New Crown Bioscience Publication Details Application of In Vitro 3D Organoids with Matched PDX for Clinically Relevan...

The paper is the first comprehensive review of tumor organoids derived from Patient Derived Xenograft (PDX) models across multiple cancer types.

Read article

What are you looking for?

9 November 2022
KBI Biopharma

Tim Lowery Appointed Interim CEO of KBI and Selexis

Tim Lowery, President of JSR Life Sciences, has been named as interim CEO to two of our core Group companies, KBI Biopharma, Inc. and Selexis SA. A search for a permanent CEO is underway.

31 October 2022
KBI Biopharma

KBI Biopharma and Selexis SA Expand Executive Leadership Team with the Appointment of Abdelaziz Toumi, Ph.D. as Chief...

KBI Biopharma, Inc. (KBI) and Selexis SA (Selexis) today announced that Abdelaziz Toumi, Ph.D., will begin serving as the companies’ Chief Business Officer.

25 October 2022
JSR Life Sciences

Similis Bio Partners With Blau Farmaceutica to Co-Develop Four Biosimilar Programs

The agreement assigns rights to four biosimilar programs across a broad range of indications to Blau for commercialization.

27 September 2022
Crown Bioscience

Crown Bioscience & MBL Launch Joint Venture to Serve Japanese Biopharmaceutical Community

Crown Bioscience & MBL, a joint venture between two JSR Life Sciences companies formed earlier this year, announce today the launch of their full-service drug discovery and development capabilities...

27 September 2022
JSR Corporation

Ajinomoto Co., Inc. and JSR Corporation Agree to Collaborate in Development of Global Biopharmaceutical Culture Media...

Ajinomoto Co. has reached an agreement with JSR to collaborate on the global expansion of its biopharmaceutical culture media business, adding new high-performance media developed by JSR, to Ajinom...

26 September 2022
MBL

MBL Launches a Kit for Simultaneous Detection of SARS-CoV-2 and Influenza Virus Antigens

This kit detects the SARS-CoV-2 antigen, influenza A virus antigen, and influenza B virus antigen in nasopharyngeal or nasal swab fluid using an immunochromatographic method.

View news archive

1 December 2022
Crown Bioscience

New Crown Bioscience Publication Details Application of In Vitro 3D Organoids with Matched PDX for Clinically Relevan...

The paper is the first comprehensive review of tumor organoids derived from Patient Derived Xenograft (PDX) models across multiple cancer types.

9 November 2022
KBI Biopharma

Tim Lowery Appointed Interim CEO of KBI and Selexis

Tim Lowery, President of JSR Life Sciences, has been named as interim CEO to two of our core Group companies, KBI Biopharma, Inc. and Selexis SA. A search for a permanent CEO is underway.

25 October 2022
JSR Life Sciences

Similis Bio Partners With Blau Farmaceutica to Co-Develop Four Biosimilar Programs

The agreement assigns rights to four biosimilar programs across a broad range of indications to Blau for commercialization.

27 September 2022
Crown Bioscience

Crown Bioscience & MBL Launch Joint Venture to Serve Japanese Biopharmaceutical Community

27 September 2022
JSR Corporation

Ajinomoto Co., Inc. and JSR Corporation Agree to Collaborate in Development of Global Biopharmaceutical Culture Media...

26 September 2022
MBL

MBL Launches a Kit for Simultaneous Detection of SARS-CoV-2 and Influenza Virus Antigens

This kit detects the SARS-CoV-2 antigen, influenza A virus antigen, and influenza B virus antigen in nasopharyngeal or nasal swab fluid using an immunochromatographic method.

View news archive

1 December 2022
Crown Bioscience

New Crown Bioscience Publication Details Application of In Vitro 3D Organoids with Matched PDX for Clinically Relevan...

The paper is the first comprehensive review of tumor organoids derived from Patient Derived Xenograft (PDX) models across multiple cancer types.

27 September 2022
Crown Bioscience

Crown Bioscience & MBL Launch Joint Venture to Serve Japanese Biopharmaceutical Community

28 July 2022
Crown Bioscience

Crown Bioscience Appoints Michael Prosser as Chief Business Officer and Illustrates Further Investment in Commercial ...

Crown Bioscience announced today that it has restructured its commercial leadership team by creating a new Chief Business Officer (CBO) role and with additional investment in commercial talent.

12 May 2022
Crown Bioscience

Crown Bioscience and MBL Enter Joint Venture to Provide Advanced Preclinical Services for Japanese Customers

Crown Bioscience and MBL announce the formation of a joint venture, to further expand the provision of Crown Bioscience’s preclinical services to Japanese customers.

28 April 2022
Crown Bioscience

First Clinical Candidate Developed using HUB Organoids® and High Content Screening Targets Cancer Stem Cells in Solid...

Crown Bioscience, a JSR Life Sciences company, and HUB Organoids (HUB) announced today the publication of preclinical data in the journal, Nature Cancer, on a bispecific antibody which prevents the...

8 December 2021
Crown Bioscience

Crown Bioscience Expands UK Facilities to Enable Growth of In Vivo Services

Upgraded facility increases capacity for in vivo services by 30 percent and adds high frequency ultrasound capabilities to the company’s preclinical capabilities

View news archive

9 November 2022
KBI Biopharma

Tim Lowery Appointed Interim CEO of KBI and Selexis

Tim Lowery, President of JSR Life Sciences, has been named as interim CEO to two of our core Group companies, KBI Biopharma, Inc. and Selexis SA. A search for a permanent CEO is underway.

31 October 2022
KBI Biopharma

KBI Biopharma and Selexis SA Expand Executive Leadership Team with the Appointment of Abdelaziz Toumi, Ph.D. as Chief...

KBI Biopharma, Inc. (KBI) and Selexis SA (Selexis) today announced that Abdelaziz Toumi, Ph.D., will begin serving as the companies’ Chief Business Officer.

8 September 2022
Selexis

Selexis and NexImmune Sign Service Agreement to Advance Multiple Immunotherapies Targeting Rare Cancers and Autoimmun...

Agreement supports the development of molecules targeting acute myeloid leukemia, multiple myeloma, human papilloma virus (HPV) associated tumors, and additional human leukocyte antigens (HLAs) tha...

6 July 2022
KBI Biopharma

KBI Biopharma and Selexis Hold Joint Ribbon Cutting of the Expanded State-of-the-Art Facility in Geneva, Switzerland

The KBI and Selexis co-location will expand biopharmaceutical development and manufacturing capabilities to serve the global demand for novel therapies.

14 June 2022
KBI Biopharma

KBI Biopharma SA and Selexis SA Expand in Europe by Opening an Integrated Biologics Manufacturing Facility in Geneva,...

KBI Biopharma and Selexis, announced today that an expanded, fully-integrated mammalian contract development and manufacturing services facility is now open and operational in Geneva, Switzerland.

11 May 2022
Selexis

Great Place to Work® Designates Selexis as a Best Workplace in Switzerland for Fifth Straight Year

Selexis SA announced today that Great Place to Work® has designated the Company among the “Best Workplaces Switzerland™” in 2022. This is the fifth straight year Selexis has earned this recognition.

View news archive

9 November 2022
KBI Biopharma

Tim Lowery Appointed Interim CEO of KBI and Selexis

Tim Lowery, President of JSR Life Sciences, has been named as interim CEO to two of our core Group companies, KBI Biopharma, Inc. and Selexis SA. A search for a permanent CEO is underway.

31 October 2022
KBI Biopharma

KBI Biopharma and Selexis SA Expand Executive Leadership Team with the Appointment of Abdelaziz Toumi, Ph.D. as Chief...

KBI Biopharma, Inc. (KBI) and Selexis SA (Selexis) today announced that Abdelaziz Toumi, Ph.D., will begin serving as the companies’ Chief Business Officer.

6 July 2022
KBI Biopharma

KBI Biopharma and Selexis Hold Joint Ribbon Cutting of the Expanded State-of-the-Art Facility in Geneva, Switzerland

The KBI and Selexis co-location will expand biopharmaceutical development and manufacturing capabilities to serve the global demand for novel therapies.

14 June 2022
KBI Biopharma

KBI Biopharma SA and Selexis SA Expand in Europe by Opening an Integrated Biologics Manufacturing Facility in Geneva,...

KBI Biopharma and Selexis, announced today that an expanded, fully-integrated mammalian contract development and manufacturing services facility is now open and operational in Geneva, Switzerland.

21 April 2022
KBI Biopharma

KBI Biopharma Holds Ribbon Cutting for New Commercial Manufacturing Facility

KBI, a JSR Life Sciences company, held a ribbon-cutting at the company’s new state-of-the-art $150 million, 150,000 square-foot commercial manufacturing facility in Research Triangle Park (RTP), No...

10 March 2022
KBI Biopharma

Oragenics Engages KBI Biopharma to Support Development of the Intranasal COVID-19 Vaccine Candidate NT-CoV2-1

KBI to Produce Material for Use in Upcoming Phase 2 Clinical Trial of Oragenics’ Intranasal Vaccine Candidate

View news archive

27 September 2022
Crown Bioscience

Crown Bioscience & MBL Launch Joint Venture to Serve Japanese Biopharmaceutical Community

26 September 2022
MBL

MBL Launches a Kit for Simultaneous Detection of SARS-CoV-2 and Influenza Virus Antigens

This kit detects the SARS-CoV-2 antigen, influenza A virus antigen, and influenza B virus antigen in nasopharyngeal or nasal swab fluid using an immunochromatographic method.

1 September 2022
MBL

MBL Obtained European Quality Management System Certificate (IVDR)

The certification ensures that the CE marked diagnostic products supplied by MBL adhere to standards of quality and safety that ensure the highest level of patients’ health protection

1 August 2022
MBL

MEBGEN BRAF Kit Receives MHLW Approval as Companion Diagnostic for Use with Patients with Melanoma

MBL announced that MEBGEN™ BRAF Kit, an in vitro diagnostic reagent, was approved for detection of BRAF gene mutations (V600E or V600K) by the Ministry of Health, Labour and Welfare for production ...

12 May 2022
Crown Bioscience

Crown Bioscience and MBL Enter Joint Venture to Provide Advanced Preclinical Services for Japanese Customers

Crown Bioscience and MBL announce the formation of a joint venture, to further expand the provision of Crown Bioscience’s preclinical services to Japanese customers.

11 April 2022
MBL

MBL Launches Five-test Kit for Rapid SARS-CoV-2 Antigen Detection

This product is a five-test kit version of GLINE-2019-nCoV Ag Kit (Code No. YH-G86256) which was released on February 14th as a one test kit

View news archive

27 September 2022
JSR Corporation

Ajinomoto Co., Inc. and JSR Corporation Agree to Collaborate in Development of Global Biopharmaceutical Culture Media...

6 June 2022
JSR Corporation

JSR Invites AuB Co., Ltd. to Kawasaki Collaborative Research Facility, JSR BiRD, Challenging Value Creation in the Mi...

JSR Corporation announced today that it has entered into a facility usage agreement with AuB, a company engaged in the study of intestinal microbiota in athletes.

3 June 2022
JSR Corporation

JSR, the collaborative research facility "JSR BiRD" in Kawasaki, invites KINS Co., Ltd.

JSR Corporation announced today that it has concluded a facility use agreement with KINS Co., Ltd. (KINS), a company with a database of human microbiome.

13 April 2022
JSR Corporation

JSR and Asahi Kasei Medical Enter Co-promotion Agreement

JSR Life Sciences, LLC is pleased to announce that JSR Corporation and Asahi Kasei Medical have entered into a co-promotion agreement for bioprocess products and materials that initiated sales coll...

16 March 2021
JSR Corporation

JSR Life Sciences Completes Integration of MBL into its Family of Companies

JSR Life Sciences that the JSR Corporation has finalized the acquisition of all outstanding shares in MBL. As a result, MBL is a wholly owned subsidiary and affiliate of the JSR Life Sciences famil...